Lower Respiratory (23 targets)
Lower Respiratory (23 targets)

[Product Name]

23 Lower Respiratory Tract Pathogen and Antimicrobial Resistance Gene Nucleic Acid Detection Kit (Fluorescent PCR-Chip Method)

Lower Respiratory (23 targets)CHE-LRP23-101

[Packing Specifications]

12 tests / box

[Applicable Models]

Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer

[Download Brochure]

Lower Respiratory (23 targets)Chenghui-Multi-Disc-23-Lower-Respiratory-Tract-Pathogen-AMR-Nucleic-Acid-Detection-Kit-Brochure.pdf



No Data

Testing Process

No Data

Intended Use


23 Lower Respiratory Tract Pathogen and Antimicrobial Resistance Gene Nucleic Acid Detection Kit (Fluorescent PCR-Chip Method) is a Fluorescent PCR-Chip assay intended for the qualitative detection of pathogens and antimicrobial Resistance genes carried by pathogens in the sputum and bronchoalveolar lavage fluid of patients with lower respiratory tract infections. The pathogens that can be detected include:

  1. Streptococcus pneumoniae, 

  2. Haemophilus influenzae, 

  3. Moraxella catarrhalis, 

  4. Acinetobacter calcoaceticus-baumannii complex, 

  5. Enterobacter cloacae complex, 

  6. Escherichia coli, 

  7. Streptococcus pyogenes, 

  8. Legionella pneumophila, 

  9. Klebsiella aerogenes, 

  10. Klebsiella oxytoca, 

  11. Klebsiella pneumoniae group, 

  12. Proteus spp., 

  13. Pseudomonas aeruginosa, 

  14. Serratia marcescens, 

  15. Staphylococcus aureus, 

  16. Streptococcus agalactiae,

  17. Chlamydia psittaci* (RUO).


Remark: The CE  certificate is not yet acquired for the detection target of Chlamydia psittaci. Nevertheless, we are able to supply this test target for research use only (RUO).



The antimicrobial resistant genes that can be detected include:

  1. CTX-M, 

  2. KPC, 

  3. NDM, 

  4. Oxa48-like, 

  5. VIM, 

  6. IMP, 

  7. mecA/mecC&MREJ (MRSA). 

Clinical Challenges


Lower respiratory tract infections (LRTIs) — particularly hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and severe community-acquired pneumonia (CAP) — are a leading cause of inpatient mortality and prolonged hospital stays. Clinical diagnosis in severe care settings faces four core unmet needs:


Complex pathogen spectrum with high missed diagnosis rate
Severe LRTIs involve a broad range of pathogens, with a high proportion of mixed infections and atypical pathogens. Conventional diagnostics such as bacterial culture and single-target PCR have limited coverage, frequently missing pathogens including Legionella pneumophila and Chlamydia psittaci, and failing to provide clear etiological evidence in time.


Long turnaround time delays precision intervention
Traditional bacterial culture requires 24–72 hours to yield results, while centralized molecular testing involves lengthy sample transfer and processing workflows. Critically ill patients cannot wait for definitive diagnosis, forcing clinicians to rely on empiric broad-spectrum antibiotic therapy, which elevates the risk of treatment failure, complications and mortality.


Rising antimicrobial resistance (AMR) threatens treatment efficacy
The growing prevalence of drug-resistant strains — including carbapenem-resistant Gram-negative bacteria and methicillin-resistant Staphylococcus aureus (MRSA) — poses a severe challenge for inpatient infection control. Conventional antimicrobial susceptibility testing (AST) has a long cycle, leading to inappropriate empiric medication, further driving AMR spread and poor patient outcomes.


High access barriers for molecular testing
Traditional nucleic acid testing relies on standardized PCR laboratories and certified technical personnel, with complex pre-test workflows. It cannot support rapid on-site diagnosis in ICUs and respiratory wards, nor can it respond efficiently to nosocomial infection outbreaks, resulting in extended diagnostic turnaround time (TAT).



Core Clinical Benefits


This 23-target lower respiratory detection kit, paired with the Multi-Disc fully automated nucleic acid analysis platform, directly addresses the above clinical pain points, delivering measurable value for severe infection diagnosis:

Lower Respiratory (23 targets)

One-stop comprehensive etiological profiling

The kit covers 16 clinically prevalent lower respiratory bacterial pathogens and 7 core antimicrobial resistance genes (23 CE-marked targets in total), with an additional Chlamydia psittaci target available for research use only (RUO). A single run identifies both single and mixed infections, drastically reducing missed diagnosis rates and providing a complete picture of infection to guide precise treatment.


Rapid results to optimize antibiotic stewardship

Total testing time is only ~80 minutes, with just 1 minute of hands-on sample loading — far faster than culture-based methods. Rapid etiological and resistance results allow clinicians to promptly adjust empiric regimens, de-escalate broad-spectrum antibiotic use in time, improve prognosis for severe patients, and shorten hospital length of stay.


Real-time AMR detection to guide targeted therapy

The kit simultaneously detects key resistance markers: extended-spectrum β-lactamase (CTX-M), five major carbapenemases (KPC, NDM, OXA-48-like, VIM, IMP) and MRSA. It delivers actionable drug resistance information at the initial diagnostic stage, helping clinicians select appropriate antibiotics early, reduce treatment failure rates, and curb the spread of antimicrobial resistance.


POCT-level workflow to lower diagnostic barriers

Powered by the fully automated Multi-Disc platform, all steps — lysis, nucleic acid extraction, amplification and result analysis — are completed in a closed cartridge. No specialized molecular laboratory or trained technicians are required, enabling near-patient deployment in inpatient departments. It significantly shortens sample TAT and improves diagnostic efficiency for severe care scenarios.


Improved detection of atypical pathogens
The included Chlamydia psittaci (RUO) target fills the gap of routine LRTI testing for rare atypical pathogens, improving diagnostic yield for unexplained pneumonia and reducing the diagnostic cycle for difficult cases.


Core Product Advantages


Severe-care oriented panel design

The 23-target panel is tailored for inpatient severe LRTI scenarios, covering the majority of clinically prevalent Gram-positive, Gram-negative and atypical pathogens responsible for both community and hospital-acquired lower respiratory infections, paired with the most clinically relevant AMR markers to support precision diagnosis for hospitalized patients.


Fully automated closed sample-to-result workflow

Based on fluorescent PCR-chip technology and the Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer, the kit enables fully automated testing. All reaction steps are completed in a single disposable cartridge, with only 1 minute of manual pipetting required. No professional molecular operation expertise is needed, realizing true "sample in, result out" detection.

Lower Respiratory (23 targets)


Throughput optimized for inpatient settings

The Multi-Disc platform supports parallel testing of 4 samples per run, delivering full results in ~80 minutes. It balances speed and batch processing capacity to meet routine testing demands in ICUs, respiratory wards and clinical laboratories, as well as rapid screening needs during nosocomial infection outbreaks.


Highly reliable assay performance

The combination of mature real-time fluorescent PCR and microfluidic chip technology ensures high sensitivity and specificity, minimizing false positive and false negative results. Stable, reproducible performance provides trustworthy evidence for clinical decision-making.


Zero cross-contamination closed system

Each sample is processed in an individual sealed cartridge. Amplification products are never exposed to the external environment, fundamentally eliminating the risk of aerosol cross-contamination, reducing laboratory quality control burden and guaranteeing result accuracy.


Broad sample compatibility and regulatory compliance
Validated for sputum and bronchoalveolar lavage fluid (BALF) samples, compatible with routine clinical LRTI sampling types. All targets are CE-marked except Chlamydia psittaci (RUO), making it suitable for wide deployment in inpatient departments, ICUs, respiratory medicine and other clinical scenarios across medical institutions.